BIIB - Biogen Inc.
| Previous Close | 226.39 |
| Open | 226.99 |
| Bid | 229.95 x 800 |
| Ask | 230.12 x 1000 |
| Day's Range | 226.70 - 230.66 |
| 52 Week Range | 216.12 - 388.67 |
| Volume | 407,248 |
| Avg. Volume | 2,259,432 |
| Market Cap | 45.208B |
| Beta (3Y Monthly) | 1.85 |
| PE Ratio (TTM) | 10.65 |
| EPS (TTM) | 21.58 |
| Earnings Date | Apr 24, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 261.19 |
- CNBC Videos•18 days ago
Buy Biogen on the dip? What about AMC on the streaming wars? The viewers #AskHalftime
The "Halftime Report" traders answer viewer questions on Biogen and AMC
- Zacks•2 hours ago
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
CNW Group•3 hours agoPatients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen)
MISSISSAUGA, ON , April 22, 2019 /CNW/ - Biogen Canada welcomes the decision made by the Government of Saskatchewan allowing patients living with Spinal Muscular Atrophy (SMA) to access SPINRAZA™(nusinersen), the first and only approved medicine in the world to treat the root cause of SMA.
- Zacks•4 days ago
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
- Motley Fool•5 days ago
Here's Why Ionis Pharmaceuticals Slumped Today
Information from competitors and a collaborator sent the high-flying biotech lower.
- Motley Fool•5 days ago
2 Beaten Down Bluechips: Are They Buys?
Sometimes opportunity comes in the shape of trouble.
- Zacks•5 days ago
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•7 days ago
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.
- American City Business Journals•7 days ago
Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.
Yahoo Finance•7 days agoGoldman Sachs's 20 best stocks to invest in now
What are the best stocks to buy after a major rally amid heightened macro risks?
- Motley Fool•8 days ago
Better Buy: Gilead Sciences vs. Biogen
Which stock wins in a battle of two big biotechs?
- GlobeNewswire•10 days ago
Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an.
- InvestorPlace•11 days ago
Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock
If you're asking whether or not to buy Exelixis (NASDAQ:EXEL) stock, the answer is, "it depends." But if you're a risk-tolerant investor in search of an up-and-coming biotech doing more than a few things right, it's time to consider buying EXEL stock. Let me explain.Source: Shutterstock If there is ever going to be a so-called perfect investment, you wouldn't expect it to be a smaller-capitalization biotechnology company like Exelixis. But that's really a generalization against a group of notoriously volatile stocks most investors need to think twice about before investing in. But that's not the situation with EXEL stock.The group as a whole has a backdrop of unstable financials, FDA approvals, the next drug trial finally being "the big one" or keeping larger competitors such as a Biogen (NASDAQ:BIIB) or Merck (NYSE:MRK) at bay. EXEL stock has defied those odds since mid-2016, when its kidney cancer blockbuster Cabometyx was approved.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAgain, that's not to say EXEL stock is the perfect investment. Bottom line, those types of risks don't simply vanish. But for now, this $7.2 billion market cap stock with its attractive forward P/E of 17.6, 0.5 PEG ratio and priced at 8.5x sales is in a strong position with the success of Cabometyx and sports a solid development pipeline which may just yet, make Exelixis a household name. EXEL Stock Weekly Price Chart Looking at the weekly chart of EXEL stock and despite some of the aforementioned volatility associated with smaller-cap biotechs, it's obvious Wall Street is also a buyer of what Exelixis has accomplished thus far -- and what appears to be a promising future. * 10 Dow Jones Stocks Holding the Blue Chip Index Back After a successful corrective challenge of prior lateral resistance and 62% retracement level from EXEL stock's 2015 low to 2018 cycle high last October, shares have been trending higher in the right side of a cup-shaped weekly base. That's bullish, and that's not all.Now and with EXEL consolidating the past month in-between the 50%-62% levels, a potential breakout and assault on the prior high of $32.50 before moving to new all-time-highs is setting up for purchasing. Buying EXEL StockFor investors agreeable with the risks discussed, the recommendation is to wait for a breakout. Without clearing the 62% retracement level, which has acted as price resistance thus far, there is a greater likelihood EXEL stock's uptrend could fail until proper price confirmation reveals itself.Not that a technical failure in this case is a bad thing. A turn lower in the share price of Exelixis could lead to an eventual double-bottom challenge. But I'd rather be a buyer of EXEL stock initiating a new position as it tests support than an investor long shares on the way down.Having said that, buying EXEL stock above $25.41 and 10 cents above last month's high within the consolidation pattern is the approach I'd use for entering into a long position. And again, as risks don't simply go away, a blended stop below $23.37 makes sense. This exit contains risk to 8% and allows for enough technical wiggle room while putting oneself in a stronger position to buy EXEL during potentially much more challenging and opportunistic times ahead.Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies, related musings or to ask a question, you can find and follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock appeared first on InvestorPlace.
Bloomberg•11 days agoAn AI Firm Wants to Predict Costly Pharma Flops
A German artificial-intelligence firm had come to a different conclusion. Innoplexus AG, a closely held company based in the outskirts of Frankfurt, uses an algorithm to analyze pharma companies’ drug pipelines that it says takes more data and context into account than any other tool. Its assessment of Biogen’s aducanumab gave about a 70 percent to 90 percent chance that the trial would miss its goal.
- Benzinga•12 days ago
Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds
Last month, Biogen Inc (NASDAQ: BIIB ) halted Phase 3 trials for aducanumab in March based on results of a futility analysis conducted by an independent data monitoring committee. While the remaining ...
GuruFocus.com•13 days ago6 Predictable Guru Stocks
According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety. The company has a three out of five-star business predictability rank and, according to the discounted cash flow calculator, a 75.47% margin of safety at $25 per share. Warning! GuruFocus has detected 5 Warning Signs with BHC.
- Markit•13 days ago
See what the IHS Markit Score report has to say about Biogen Inc.
Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding BIIB is favorable, with net inflows of $140.17 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey•14 days ago
Sarissa Capital Management Hires New President
Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning 15.5%. Just for the comparison, an average activist hedge fund reported a loss of 11% in the same period, and the S&P 500 lost 4.4%. Even over the last three years, the fund […]
- Motley Fool•16 days ago
Should Biogen Investors Be Extra Nervous Right Now?
The biotech giant's most important drug is under a microscope and it doesn't look pretty.
- Simply Wall St.•18 days ago
Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it prac...
- Motley Fool•18 days ago
1 Biotech That Biogen Should Buy ... but Probably Won't
The drugmaker has $4.9 billion in the bank.
- Motley Fool•18 days ago
Why Biogen Stock Tanked in March
The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.
- Reuters•18 days ago
MOVES-Activist hedge fund Sarissa hires president in push for growth
Sarissa Capital Management LP, the activist hedge fund run by Alexander Denner that invests in pharmaceutical and healthcare companies, has hired asset management veteran Eric Vincent as president, according to his LinkedIn profile and two people familiar with the matter. Sarissa is seeking to cross the $1 billion mark in assets under management by attracting new investors at a time when demand for hedge funds is picking up again. Scale is important for firms like Sarissa, which pressure companies to adopt their proposals and give them board seats.
Reuters•19 days agoBiogen SMA drug price, Novartis estimates for its treatment far too high: U.S. group
Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday. Assessments by the nonprofit Institute for Clinical and Economic Review (ICER) have become increasingly influential in U.S. drug pricing and are taken into consideration by health insurers and pharmacy benefit managers making decisions about payments and patient access to treatments. Boston-based ICER has been looking at Biogen's Spinraza and Novartis' Zolgensma since last year.
